Prisma Health Cancer Institute - Seneca
Claim this profileSummary
Prisma Health Cancer Institute - Seneca is a medical facility located in Seneca, South Carolina. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Cancer, Non-Small Cell Lung Cancer and other specialties. Prisma Health Cancer Institute - Seneca is involved with conducting 306 clinical trials across 449 conditions. There are 8 research doctors associated with this hospital, such as Ki Chung, MD, Aniket Saha, Jeffrey K. Giguere, and Suzanne R. Fanning.Area of expertise
Breast Cancer
Prisma Health Cancer Institute - Seneca has run 60 trials for Breast Cancer. Some of their research focus areas include:
Lung Cancer
Prisma Health Cancer Institute - Seneca has run 54 trials for Lung Cancer. Some of their research focus areas include:
Top PIs
Ki Chung, MD
Prisma Health Cancer Institute - Eastside
6 years of reported clinical research
Aniket Saha
BI-LO Charities Children's Cancer Center
8 years of reported clinical research
Jeffrey K. Giguere
Prisma Health Cancer Institute - Faris
8 years of reported clinical research
Suzanne R. Fanning
Prisma Health Cancer Institute - Eastside
2 years of reported clinical research
Clinical Trials running at Prisma Health Cancer Institute - Seneca
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting
2 awards
Phase 3
27 criteria
Durvalumab
for Lung Cancer
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The usual approach for patients who are not in a study is to closely watch a patient's condition after surgery and to have regular visits with their doctor to watch for signs of the cancer coming back. Usually, patients do not receive further treatment unless the cancer returns. This study will help determine whether this different approach with durvalumab is better, the same, or worse than the usual approach of observation. Giving durvalumab may help patients live longer and prevent early-stage non-small cell lung cancer from coming back as compared to the usual approach.
Recruiting
2 awards
Phase 3
8 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting
2 awards
Phase 3
28 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Prisma Health Cancer Institute - Seneca?
Prisma Health Cancer Institute - Seneca is a medical facility located in Seneca, South Carolina. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Cancer, Non-Small Cell Lung Cancer and other specialties. Prisma Health Cancer Institute - Seneca is involved with conducting 306 clinical trials across 449 conditions. There are 8 research doctors associated with this hospital, such as Ki Chung, MD, Aniket Saha, Jeffrey K. Giguere, and Suzanne R. Fanning.